Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS-004 Appendix 1: olaparib + AZD6738 in biomarker-selected second-line metastatic pancreatic cancer
ISRCTN16004234Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of olaparib and ceralasertib in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Objective response rate. Started Nov 2020; status: terminated.
02
Drugs
olaparibceralasertib
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN16004234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16004234.